News round-up by DDW’s Reece Armstrong for 16-20 May
Drug approvals, a focus on Covid-19 and collaborative milestones are some of the themes of this week’s news round-up.
The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to Eli Lilly’s oral inhibitor abemaciclib for the treatment of patients with a specific type of breast cancer.
The National Institute of Allergy and Infectious Diseases (NIAID) is investing $577 million to establish nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern, the organisation has announced.
AstraZeneca has identified an additional target for its idiopathic pulmonary fibrosis (IPF) pipeline using an AI system designed by drug discovery company BenevolentAI.
A partnership between life sciences companies PrecisionLife and Sano Genetics aims to drive insights into the genetics of long Covid and potentially identify new treatments.
Boehringer Ingelheim’s investigational therapy for idiopathic pulmonary fibrosis (IPF) has shown positive data in a Phase II clinical trial, the company has announced.